Unclassifiable interstitial lung disease: a distinct entity with heterogeneous progression

Nasser, Mouhamad; Rigaud, Pierre; Kazemi, Ahmad; Traclet, Julie; Cottin, Vincent

doi:10.1183/13993003.congress-2018.pa2245

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…N asser et al [89] studied 71 patients with unclassifiable ILD from a national French reference centre and found progressive disease in 46 (64%). Progressors had higher mortality (p=0.004), but the only predictor of disease progression was lower baseline FVC (mean± sd 70±20% versus 84±27%; p=0.049).…”

Section: Introductionmentioning

confidence: 99%

Research highlights from the 2018 ERS International Congress: interstitial lung diseases

et al. 2019

View full text Add to dashboard Cite

This article reviews a selection of the scientific presentations on interstitial lung disease (ILD)/diffuse parenchymal lung disease (DPLD) that were made at the 2018 European Respiratory Society (ERS) International Congress in Paris. A number of advances in the epidemiology, pathogenesis, diagnosis and treatment of these disorders were presented and discussed by clinicians and researchers. The research topics span over all four groups of ERS Assembly 12: Interstitial Lung Diseases (Group 12.01: Idiopathic interstitial pneumonias; Group 12.02: ILD/DPLD of known origin; Group 12.03: Sarcoidosis and other granulomatous ILD/DPLD; Group 12.04: Rare ILD/DPLD).

show abstract

Section: Introductionmentioning

confidence: 99%